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Human cytomegalovirus (HCMV) infection remains the 
leading cause of serious contagious complications af-
ter allogeneic hematopoietic stem cell transplantation. 
These infections in HCMV-seropositive recipients can be 
due to reactivation or reinfection. Different HCMV strains 
were identified by determining the genotypes isolated 
from repeatedly tested patients. The UL55 sequences 
encoding viral glycoprotein B (gB) have been chosen as 
the target gene. The region, in which the gB precursor 
protein is cleaved into two fragments by a cellular en-
doprotease, is characterized by genetic variability, and 
based on that HCMV is classified into four major geno-
types: gB1, gB2, gB3 and gB4. Multiplex real-time PCR 
assay enabled both, HCMV gB genotyping, as well as 
simultaneous quantitative assessment of the detected 
genotypes. This study was carried out in 30 transplant 
recipients, from whom 105 isolates of HCMV DNA were 
genotyped. In 40% of recipients, a mixed infection with 
two or three genotypes was detected. Genotype gB1 
dominated in general, and characteristically for mixed 
infections, the genotype gB3 or gB4 was always present. 
Although there were no significant differences in the 
load for each genotype, in case of multiple infections, 
the number of copies of gB1 genotype was significantly 
higher when compared to a single gB1 infection. In pa-
tients with mixed genotypes, chronic HCMV infections 
and graft versus host disease were observed more often, 
as well as antiviral treatment was less effective. It was 
assumed that these adverse effects can be related to the 
presence of gB3 and gB4 genotypes.
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INTRODUCTION
Human cytomegalovirus (HCMV) is a major cause of 
morbidity and mortality among immunocompromised 
patients, especially those who undergo transplantation 
or suffer from either malignant hematologic disease or 
AIDS. In the absence of any form of preventive inter-
vention, HCMV infection develops in 30% to 80% of 
transplant recipients, resulting in symptomatic disease in 
7% to 33% of them (Ljungman et al., 2010; Linares et al., 
2011). HCMV does not only directly cause morbidity and 
occasional mortality, but also induces many short-term 
and long-term indirect effects that collectively contrib-
ute to allograft rejection and diminished patient survival. 
Prevention of HCMV infection and disease is, therefore, 
essential to ensure a successful outcome of transplanta-
tion (Kotton et al., 2010; Razonable et al., 2013).
Transplant recipients develop HCMV disease either as 
a primary infection (when HCMV is transmitted through 
the transplanted allograft to a HCMV-naive recipient), a 
reactivation infection (when an endogenous latent virus 
reactivates after transplantation) or as reinfection (when 
donor-transmitted virus is superimposed on an endog-
enously reactivated virus). While primary HCMV infec-
tion is considered to be the most serious in solid organ 
transplant recipients, secondary infections, resulting from 
virus reactivation or superinfection with different strains, 
are the highest risk for developing HCMV disease in al-
logeneic hematopoietic stem cell transplant (allo-HSCT) 
recipients (Boeckh & Nichols, 2004).
The aim of this study was to apply multiplex real-time 
PCR to determine the genotype of glycoprotein B (gB) 
of HCMV strains isolated from blood of seropositive 
patients subjected to allo-HSCT. This glycoprotein, as 
an integral component of the viral envelope encoded by 
the UL55 gene, is the main target for both, humoral and 
cellular immune responses. It also fulfills a key role in 
the adsorption and penetration of HCMV into the target 
cell, as well as in the spread of infection from cell to 
cell. In these processes, the gB molecule serves as the 
fusion protein and, in cooperation with other membrane 
glycoproteins of the envelope, triggers an entry fusion 
and allows entry of the virus into cells (Vanarsdall et al., 
2012; Wille et al., 2013).
The region included between codons 448–481 of 
UL55 gene, in which the gB precursor protein is cleaved 
into two fragments by a cellular endoprotease, is char-
acterized by genetic variability, enabling the division of 
HCMV into four major genotypes: gB1, gB2, gB3 and 
gB4 (Pignatelli et al., 2004; Isaacson & Compton, 2009).
We hypothesized that distinction of superinfection 
from the episodes of reactivation of virus with the same 
genotype would be possible by gB genotyping and com-
paring HCMV isolates obtained from the same recipient, 
repeatedly tested at different time points after transplan-
tation. Additionally, the consequences of such HCMV 
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infections with multiple or single gB genotype after allo-
HSCT were analyzed.
MATERIALS AND METHODS
Study population. We enrolled thirty HCMV-sero-
positive patients (12 female and 18 male, a median over-
all age of 36 years) with active HCMV infection con-
firmed according to the standard diagnostic procedure, 
who received allo-HSCT from matched sibling donor 
between 2004 and 2009, at the Chair of Hematology, 
Jagiellonian University Medical College in Kraków.
Indications for allo-HSCT were: acute lymphoblastic 
leukemia (N=7), acute myeloid leukemia (N=11), chron-
ic myeloid leukemia (N=6) and other hematologic dis-
eases (N=6). Serological status of donor-recipient pairs 
was determined by ELISA using Enzygnost anti-CMV 
IgG/IgM kits (Simens Healthcare, Germany). Only 4 re-
cipients received cells from seronegative donors.
The patients were monitored at least once a week 
until 100th day after transplantation, thereafter every 2 
weeks for 6 months, or when there were clinical indica-
tions.
Active HCMV infection was defined as the detection 
of viral DNA in two consecutive blood samples. HCMV 
disease or syndrome was defined according to the pub-
lished recommendations (Ljungman et al., 2002).
All the recipients during the neutropenic phase re-
ceived standard prophylactic therapy against infections, 
i.e. oral ciprofloxacin, fluconazole, and acyclovir. Cotri-
moxazole was administered as prophylaxis against Pneu-
mocystis jiroveci during conditioning until 2 days before 
transplantation, restarted after engraftment and contin-
ued for at least 6 months. For preemptive anti-HCMV 
therapy in recipients with asymptomatic active HCMV 
infections, two therapeutic schemes were used, i.e. gan-
ciclovir (5 mg/kg × 2) intravenously for either 14 days 
or until two consecutive results were negative, or gan-
ciclovir for 7 days followed by 5 days a week until the 
disappearance of viral DNA in the PCR test. The dose 
of ganciclovir was modified according to creatinine clear-
ance. In the case of suspected myelosuppression induced 
by ganciclovir, foscarnet was administered at an inducing 
dose of 60 mg/kg every 12 hours, and then a supporting 
dose of 60 mg/kg/day. In the treatment of HCMV dis-
ease, either ganciclovir (10 mg/kg/day) or foscarnet (120 
mg/kg/day) was used with intravenous immunoglobulin 
preparations. In individual cases, cidofovir was adminis-
tered at an inducing dose of 5 mg/kg once a week, fol-
lowed by a maintenance therapy every other week.
The study on monitoring infections with herpesvirus-
es in allo-HSCT recipients was approved by the Ethical 
Committee of Jagiellonian University.
Virus isolates and clinical specimens. A hundred 
and five HCMV DNA samples of clinical isolates ob-
tained during the prospective monitoring of recipients 
were included in the gB genotyping. The DNA samples 
were extracted from aliquots of 1x106 peripheral blood 
leukocytes (PBL) using Genomic DNA Prep Plus (A&A 
Biotechnology, Poland). Separation of PBL was per-
formed in 6% dextran (MW 60, 000) according to the 
method described by The and coworkers (1995).
The load of HCMV DNA was quantified by using the 
Q-CMV Real Time Complete kit (Nanogen Advanced 
Diagnostics, Italy). The samples were stored at –70°C 
until tested.
The prototype strains of HCMV: gB1 — Towne 
(ATCC — VR-977) and gB2 — AD-169 (ATCC — VR-
538) were used to prepare calibration curves.
HCMV gB genotyping. Multiplex real-time PCR was 
used for HCMV gB genotyping, in which the mixture of 
primers and minor-groove DNA-binding (MGB) probes 
labeled with VIC and FAM fluorophores allowed the si-
multaneous detection of not only the genotypes, but also 
their quantitative assessment. The sequence of primers 
and probes, and PCR conditions were established ac-
cording to Pang and coworkers (2008). The amplification 
products were similar in length, 72–79 bp depending on 
the genotype. All four genotypes were detected in one 
reaction, in two separate tubes (separately for gB1 and 
gB3 and adequately for gB2 and gB4). The reaction 
mixture with a final volume of 20 μl contained: 10 μl 
of TaqMan Fast Universal PCR Master Mix (Applied 
Biosystems), 400 nM primers and 200 nM of the corre-
sponding MGB-probes, and 4 μl of DNA isolated from 
1 × 106 PBL. The reaction was performed with the Ap-
plied Biosystems 7500 Fast Real-Time PCR System. Se-
rially diluted DNA derived from the prototype gB1 and 
gB2 strains was amplified in parallel with each reaction 
to determine the calibration curves. Water and DNA ex-
tracted from PBL of an HCMV-seronegative donor were 
used as negative controls of amplification.
Statistical analysis. All viral load results were trans-
formed to log10 values. Descriptive statistics were used 
to calculate the incidence of gB genotypes. The results 
were expressed as a mean or median ± S.D. Continu-
ous variables were analyzed by the U Mann–Whitney or 
ANOVA tests, with values of P < 0.05 considered sig-
nificant. Dichotomous variables were analyzed using the 
chi-square test or Fisher’s exact test. The statistical anal-
ysis was done using the STATISTICA PL 10.0 software.
RESULTS
The study was performed in 30 allo-HSCT recipi-
ents (all HCMV-seropositive), from whom 105 clini-
cal isolates of HCMV were selected for gB genotyping 
Table 1. Distribution and prevalence of gB genotypes in 30 allo-HSCT recipients.
Initially, infection with one genotype was found in 26 patients, and co-infection with two genotypes in 4 patients. In subsequent sam-
ples, superinfection with one or two new genotypes was demonstrated in 9 recipients (8 from initially single-genotype, and one from the 
group of co-infection).
Genotypes Initial single-genotype infections1 (%)
Mixed infections
Total No. (%) of genotypes1
Co-infection Superinfection
gB1
gB2
gB3
gB4
13 (43.3)
3 (10.0)
5 (16.7)
5 (16.7)
3
1
2
2
4
3
2
1
20 (66.7)
7 (23.3)
9 (33.3)
8 (26.7)
No. of patients 26 4 9 30
1The difference between the gB1 prevalence and other gB genotypes was statistically significant (P < 0.02, Fisher’s exact test).
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in follow-up observation ranging from 2–46 months 
(mean 15.8 months). Each patient was repeatedly ex-
amined for genotyping, an average of 3.5    ± 2.9 times. 
The mean time between allo-HSCT and the first pos-
itive PCR result confirming the presence of HCMV 
was 53.5 days.
The initial genotyping of HCMV clinical isolates re-
vealed infection with one genotype in 26 (87%) recip-
ients and co-infection with two genotypes in 4 (13%) 
patients. In analysis of the subsequent samples, su-
perinfection with other genotypes was identified in 9 
(30%) recipients (Fig. 1).
The time from the occurrence of the initial geno-
type to detection of superinfection ranged from 8 to 
more than 300 days, on average over 3 months. In the 
remaining patients with only one genotype, secondary 
infection was also observed, probably as a result of 
reactivation or reinfection, but due to virus with the 
same gB genotype. The distribution of the different 
genotypes, including co-infections and superinfections 
is summarized in Table 1. Twelve (40%) out of the 
30 analyzed recipients were infected with more than 
one gB genotype of HCMV (2 and 3 genotypes were 
confirmed in 10 and 2 patients, respectively). Geno-
type gB1 dominated generally, and for mixed infec-
tions it was characteristic that the gB3 or gB4 gen-
otype was always present. Genotype gB3 or gB4 was 
detected in only 4 out of 18 recipients with a single 
gB-genotype infection.
The number of viral copies (load) was significantly 
higher (4.3 times on average) in samples with mixed 
genotypes than in samples with a single genotype (Fig. 
2). Although there were no significant differences 
in the values  of load for each genotype (Fig. 3), in 
samples with multiple gB-genotypes the copy num-
ber of gB1-genotype increased significantly (P = 0.02; 
U Mann–Whitney test). No such relationship was ob-
served for the other genotypes. The results are shown 
in Table 2.
In the clinical evaluation, because of a small group 
of patients studied, it was difficult to analyze the im-
pact of the individual genotype on the course of the 
infection. Therefore, the clinical course of HCMV 
infection was compared in two groups of allo-HSCT 
recipients: patients infected with a single gB-genotype 
(N=18) and with multiple gB-genotypes as a result of 
co-infection and/or superinfection (N=12).
Asymptomatic infection occurred more frequent-
ly in persons infected with one genotype when com-
pared to multiple genotypes (in 33% and 8% recipi-
Figure 1. Superinfection with different gB genotypes of HCMV, which was observed in 9 allo-HSCT recipients in the months follow-
ing transplantation.
Initials of patients, sex and age, and anti-HCMV serologic status between donor–recipient (D/R) at the time of transplantation are pre-
sented. Dots indicate a blood sample, in which the presence of HCMV is confirmed, gB genotype type is marked with a digit.
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ents, respectively), but this difference was not statisti-
cally significant.
HCMV disease developed in individual recipients in 
both groups and it manifested as gastroenteritis, hepatitis, 
and retinitis. Increase in transaminases, thrombocytope-
nia and anemia occurred in both groups of patients with 
similar frequencies. The differences were not statistically 
significant. It was characteristic, however, that in patients 
with mixed genotypes, recurrences and chronic HCMV 
infections were observed more often, as well as acute or 
chronic form of graft versus host disease (GvHD). Anti-
viral treatment results were also less effective in recipients 
infected with mixed genotypes. The anti-HCMV therapy 
had to be repeated in 90% of these patients. The results 
of this analysis are presented in Table 3.
DISCUSSION
The method applied by us, with the use of specific 
MGB DNA probes of great sensitivity, allowed the si-
multaneous detection of not only the gB genotypes of 
HCMV but also their quantitative assessment, which in 
the case of co-infection gave the opportunity to deter-
mine the mutual quantitative proportions between gen-
otypes. The presence of two or three genotypes in the 
randomly selected HCMV clinical isolates was confirmed 
in even 25% (26/105) of samples.
Based on the gB genotyping, the preliminary hypoth-
esis about the possible and common reinfections with 
different strains of HCMV after hematopoietic stem cell 
transplantation was confirmed. The results showed that 
the presence of specific antibodies in the transplant re-
cipient fails to protect such person against secondary in-
fections and disease progression. Although differences in 
the incidence of HCMV disease in the compared groups 
of patients did not differ significantly, less frequent cases 
of asymptomatic patients with multiple genotype infec-
tions in comparison to infection with only one gB geno-
type were reported.
In patients with mixed infections, a severe course of 
infection was observed more frequently, as is evidenced 
by: significantly higher levels of viral DNA found in pe-
ripheral blood, more frequent relapses, the tendency to 
chronic infection and failure of antiviral therapy.
These adverse effects observed in cases with multi-
ple infections could be related to the presence of gB3 
and gB4 genotypes, which give, as already suggested by 
other authors, greater immuno- and myelosuppression 
in comparison to gB1 and gB2 genotypes (Fries et al., 
1994; Torok-Storb et al., 1997; Randolph-Habecker et al., 
2002). Also, Xia et. al. (2012) reported statistically signif-
icant lower rates of viral clearance in Chinese HSCT-re-
cipients at day 21 of therapy, and more frequent HCMV 
reactivation/reinfection in patients infected with the gB3 
genotype, than in those infected with the gB1 genotype.
The distribution of CMV gB genotypes seems to be 
associated with geographic and/or demographic differ-
ences among patients. In our study, the frequency of 
occurrence of each genotype assessed by a single geno-
typing assay was similar to that described with the use 
of distinct techniques in solid organ and bone marrow 
Figure 2. The HCMV load calculated per million PBL in samples 
with single and mixed gB genotypes estimated by commercial 
Q-CMV Real Time Complete kit.
The differences were statistically significant (P = 0.0004, U Mann–
Whitney test). CI, confidence interval for mean
Figure 3. Comparison of the HCMV load for each gB genotype 
in 105 samples of 30 allo-HSCT recipients.
Table 2. Viral load for each gB genotype of HCMV determined 
in 105 samples of 30 allo-HSCT recipients with regard to single- 
and multiple-genotype samples.
Genotype  No. (%) mean* S.D. median*
Single-gB genotype1 N = 79
gB1 48 (60.76)3 2.752 0.65 2.78
gB2 7 (8.86) 2.51 0.24 2.46
gB3 12 (15.19) 3.24 1.08 3.41
gB4 12 (15.19) 2.45 1.15 2.54
Multiple-gB genotype1 N = 26
gB1 23 (88.5)4 3.112 0.81 3.17
gB2 6 (23.1) 3.17 0.69 3.04
gB3 7 (26.9) 3.16 0.58 2.99
gB4 19 (73.1)4 3.03 0.87 2.92
*log10 of HCMV copy number /million PBL; S.D., standard deviation; 
1Differences between the median viral loads not significant for indi-
vidual gB genotypes (P > 0.05, ANOVA Kruskal–Wallis test); 2Differences 
between the gB1 viral loads in samples with single- and multiple-gen-
otype were statistically significant (the Mann-Whitney U test, P = 0.02); 
3The difference between the gB1 prevalence and other gB genotypes 
was statistically significant (P < 0.0001 Fisher’s exact test ); 4The differ-
ence between the prevalence of gB1 and gB4 genotypes and gB2 and 
gB3  genotypes was statistically significant (P < 0.001, Fisher’s exact 
test).
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cells’ transplant recipients in the European countries 
and North America. A characteristic observation in our 
research was the dominance of gB1 genotype over the 
other genotypes, which was also confirmed by others 
(Fries et al., 1994; Rubalova et al., 2010; Pang et al., 2008; 
Manuel et al., 2009). In contrast, some data reported in 
HSCT recipients from Japan and China indicated dif-
ferent distribution of gB genotypes with the dominance 
of gB2 or gB3 genotypes (Wada et al., 1997; Wu et al., 
2010). However, Xia et. al. (2012) revealed with a pro-
spective analysis of 102 HSCT recipients that the gB1 
genotype was the most prevalent among Chinese pa-
tients.
Possibly due to monitoring of HCMV infection for 
months following transplantation, and repeated genotyp-
ing , the incidence of a mixed infection has been affect-
ed in our studies, i.e. it has increased from 13% to 40% 
of recipients. This result differs markedly from the fre-
quency cited by other authors, showing such gB-multi-
ple infections much less often, i.e. in 2.5% (Torok-Storb 
et al., 1997), 6.3% (Fries et al., 1994) and in 17% of al-
lo-HSCT recipients (Rubalova et al., 2010). Furthermore, 
these authors used RFLP (Restriction Fragment Length 
Polymorphism) method for determination of the gB gen-
otype, which could also result in a lower frequency of 
detection of a mixed infection (Sowmya et al., 2007).
Comparison of viral load for gB1, gB2, gB3 and gB4 
genotypes showed no significant differences, but the 
mean and median values in the samples, in which the 
gB3 genotype was present, were the highest (Fig. 3). A 
similar relationship was reported by Manuel and cowork-
ers (2009) in patients subjected to organ transplantation, 
when the copy number was evaluated in DNA extracted 
from whole blood. The role of the gB3 genotype in the 
pathogenesis of HCMV infection appears to be partic-
ularly interesting in the context of the study by Torok-
Storb and coworkers (1997), analyzing mortality in re-
cipients of bone marrow cells due to myelosuppression, 
which showed a significant correlation of the increase in 
this parameter with infections caused by gB3 and gB4 
genotypes of HCMV. The risk of death associated with 
neutropenia in patients infected with these genotypes 
was more than 12-fold higher than in patients infected 
with gB1 and gB2 genotypes. In our study we found a 
significant association between mixed infections and the 
presence of gB3 and gB4 genotypes, which could be im-
portant in the development of chronic HCMV infection 
and GvHD in enrolled recipients.
In patients with mixed infections, co-infections with 
two or three genotypes were characterized by a signifi-
cantly higher load (P = 0.0001) than in blood samples, in 
which only one genotype was present, and these differ-
ences for the assessed individual genotypes were prefera-
bly revealed for gB1 genotype (Fig. 2 and Table 2). This 
trend may indicate interactions between co-existing gen-
otypes and stimulation of HCMV replication of one gen-
otype by another one. Lack of significantly higher values 
of load for the other genotypes in mixed infections can 
probably be explained by the small number of samples, 
not representative of a full statistical analysis, in which 
they were detected. It should be noted that some authors 
have also pointed out a higher number of HCMV copies 
in mixed infections when compared to those caused by 
a single genotype (Pang et al., 2008; Manuel et al., 2009). 
On the other hand, Humar et al. (2003) did not observe 
such differences, but the adverse effects of a mixed in-
fection were connected with longer time necessary to 
eradicate the virus. In allo-HSCT recipients with multiple 
genotype infections enrolled in our study, antiviral ther-
apy results were also significantly worse than in patients 
with single-genotype infections.
In conclusion, simultaneous identification of HCMV 
gB genotypes with measurement of their loads in test-
ed samples could provide important information for al-
lo-HSCT recipients with HCMV viremia. Understanding 
the relationship between different HCMV strains may be 
very important for comprehension of the pathogenesis 
of this disease and improvement of the clinical manage-
ment of immunocompromised patients.
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